Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis
Figure 4
Serum miR-125b predicts rituximab response in B lymphoma patients. Expression levels of miR-125b were quantified by RT-qPCR as described in M&M in the serum of patients with B lymphoma before initiation of rituximab treatment. Clinical response was analyzed 4–6 weeks later and patients were considered nonresponders (NR, ) or responders (R, ) according to international recommendations.
